Thank you for providing the transcripts. Based on the information provided, here is a summary of the key financial metrics for the recent earnings conference call:

1. Non-acquired growth for Q1 was 3.8%, which is within the expected range of 3.5% to 4.5% annually.
2. Adjusted operating income for the quarter was $380 million, a decrease compared to the fourth quarter of 2016.
3. It was noted that the decrease in operating income was due to normal seasonal factors and swing factors including lower enrollment on patient ACA plans, increase in clinical teammate wages, decline in adjusted operating income in pharmacy operations, and higher revenue due to forecasted commercial rate decreases taking place later in the year.
4. Other factors contributing to adjusted operating income for Kidney Care were temporary decrease in compensation accruals in 2017, and lower EPO pricing from a renegotiated contract with Amgen. Additionally, a government settlement of $538 million was received in March.
5. The acquisition of Renal Ventures, and the extension of partnership with Humana to provide integrated care services were highlighted as significant developments for the company.
6. The 2017 Kidney Care adjusted operating income guidance was reaffirmed at $1.525 billion to $1.625 billion, with a note of greater uncertainty due to potential healthcare reform efforts.
7. The discussion on DMG included the impact of out-of-network rates, inventory wind down, and flu season on financial performance.

Overall, the financial performance of the company in Kidney Care and DMG was discussed in detail, providing insight into the key business drivers and factors affecting the financial metrics. The company is monitoring the impact of potential healthcare reform efforts on its business and remains focused on its financial guidance for 2017.